Trial Profile
A Phase II Clinical Trial to Evaluate Amplige as Part of a Combination Therapy in Brain-Metastatic Breast Cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2020
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary) ; Dendritic cell vaccines; Interferon alpha-2b
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 30 Oct 2020 According to an AIM ImmunoTech media release, the company expects to initiate this study in the 2020-21 .
- 04 Oct 2019 New trial record
- 24 Sep 2019 According to an AIM ImmunoTech media release, this and other phase II trial (CT profile 313473) are separate but parallel proposed clinical trials and are receiving approximately $15 million in DoD funding to study Ampligen as a tumor microenvironment modulating agent component of a dendritic cell vaccine approach in the treatment of brain-metastatic breast cancer.